These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14741112)

  • 21. Continuous glucose monitoring and external insulin pump: towards a subcutaneous closed loop.
    Hanaire H
    Diabetes Metab; 2006 Dec; 32(5 Pt 2):534-8. PubMed ID: 17130814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hybrid Closed-Loop System: Evolution and Practical Applications.
    Weaver KW; Hirsch IB
    Diabetes Technol Ther; 2018 Jun; 20(S2):S216-S223. PubMed ID: 29873517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attempts at perfect normalization of glucose tolerance test of severe diabetics by artificial beta cell.
    Kerner W; Thum C; Tamás G; Beischer W; Clemens AH; Pfeiffer EF
    Horm Metab Res; 1976 Jul; 8(4):256-61. PubMed ID: 783030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous glucose monitoring and pumps.
    Cohen N
    Aust Fam Physician; 2015 May; 44(5):284-7. PubMed ID: 26042400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiology, pathology and pharmacology of insulin secretion: recent acquisitions.
    Malaisse WJ
    Diabetes Metab; 1997 Sep; 23 Suppl 3():6-15. PubMed ID: 9342537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico evaluation platform for artificial pancreatic beta-cell development--a dynamic simulator for closed-loop control with hardware-in-the-loop.
    Dassau E; Palerm CC; Zisser H; Buckingham BA; Jovanovic L; Doyle FJ
    Diabetes Technol Ther; 2009 Mar; 11(3):187-94. PubMed ID: 19191486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Closing the Loop on Exercise in Type 1 Diabetes.
    Bally L; Thabit H
    Curr Diabetes Rev; 2018; 14(3):257-265. PubMed ID: 28245784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term application of wearable artificial endocrine pancreas--closed-loop intravenous vs subcutaneous insulin infusion.
    Shichiri M; Kawamori R; Goriya Y; Yamasaki Y; Nomura M; Asakawa N; Kubota M; Kamada T
    Life Support Syst; 1985; 3 Suppl 1():583-7. PubMed ID: 3916624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The artificial pancreas.
    Brunetti P; Orsini Federici M; Massi Benedetti M
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):127-38. PubMed ID: 12751831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled drug delivery in the treatment of diabetes mellitus.
    Irsigler K; Kritz H; Lovett RG
    Crit Rev Ther Drug Carrier Syst; 1985; 1(3):189-280. PubMed ID: 3912064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor.
    Finan DA; Dassau E; Breton MD; Patek SD; McCann TW; Kovatchev BP; Doyle FJ; Levy BL; Venugopalan R
    J Diabetes Sci Technol; 2015 Jun; 10(1):104-10. PubMed ID: 26134834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin pumps and glucose regulation.
    Thompson JS; Duckworth WC
    World J Surg; 2001 Apr; 25(4):523-6. PubMed ID: 11344407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of implantable biosensors for closed-loop glucose control and other drug delivery applications.
    Scholten K; Meng E
    Int J Pharm; 2018 Jun; 544(2):319-334. PubMed ID: 29458204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New perspectives on the structure and function of the normal and diabetic beta-cell.
    Hellerström C; Eizirik DL; Welsh N; Sjöholm A; Jansson L; Svensson C; Strandell E; Korsgren O; Li ZQ; Andersson A
    Ups J Med Sci; 1991; 96(1):1-16. PubMed ID: 1897059
    [No Abstract]   [Full Text] [Related]  

  • 36. Feasibility of automating insulin delivery for the treatment of type 1 diabetes.
    Steil GM; Rebrin K; Darwin C; Hariri F; Saad MF
    Diabetes; 2006 Dec; 55(12):3344-50. PubMed ID: 17130478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
    Christiansen JS; Svendsen PA; Deckert T
    Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes.
    P V J; Nair SV; Kamalasanan K
    Colloids Surf B Biointerfaces; 2017 May; 153():123-131. PubMed ID: 28235722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous glucose monitoring and closed-loop systems.
    Hovorka R
    Diabet Med; 2006 Jan; 23(1):1-12. PubMed ID: 16409558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal diabetes and insulin pump therapy.
    Beardsall K; Pesterfield CL; Acerini CL
    Arch Dis Child Fetal Neonatal Ed; 2011 May; 96(3):F223-4. PubMed ID: 21115555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.